This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutTherapeutic IndicationsRheumatoid arthritisJuvenile idiopathic arthritisPsoriatic arthritisAxial spondyloarthritisPlaque psoriasis & Paediatric plaque psoriasisMechanism of actionMechanism of actionDosingDosingRheumatoid arthritis, psoriatic arthritis & axial spondyloarthritisJuvenile idiopathic arthritisPlaque psoriasisPaediatric plaque psoriasisAdministration & storageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacy & SafetyRheumatoid arthritisAxial spondyloarthritisPsoriatic arthritisPlaque psoriasisJuvenile idiopathic arthritisSupport & ResourcesMaterials
Enbrel for Rheumatoid ArthritisRheumatoid Arthritis Indication for Enbrel

Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active RA in adults when the response to DMARDs, including methotrexate (unless contraindicated), has been inadequate.1

Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.1

Enbrel is also indicated in the treatment of severe, active and progressive RA in adults not previously treated with methotrexate.1

Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.1

Contraindications
  • Hypersensitivity to the active substance or to any of the excipients1
  • Sepsis or risk of sepsis1
  • Treatment with Enbrel should not be initiated in patients with active infections, including chronic or localised infections1​​​​​​
Rheumatoid Arthritis Dosing

Enbrel treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of RA. Patients treated with Enbrel should be given the Patient Alert Card.1

25 mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50 mg administered once weekly has been shown to be safe and effective.1

Clinical efficacy

Enbrel is efficacious both in combination with MTX and in monotherapy. Enbrel inhibits radiographic progression alone and in combination with MTX in moderate to severe RA.2,3

Further information on the clinical efficacy and safety of Enbrel in monotherapy and in combination with MTX, please refer to the Enbrel SmPC​​​​​​​.

Enbrel monotherapy in RA patients

The TEMPO trial was a double-blind, randomised parallel group study in 686 patients with active, adult-onset RA. Subjects were randomised to receive Enbrel alone (25 mg Enbrel twice weekly + placebo); MTX alone (7.5 mg orally every week up to 20 mg within 8 weeks if the patient had any painful or swollen joints + placebo) or combination therapy (25 mg subcutaneous Enbrel injections twice a week + oral MTX once a week). The primary efficacy endpoint was the numeric index of the ACR response area under the curve over the first 24 weeks. The primary radiographic endpoint was the change from baseline to Week 52 in total joint damage, assessed with the modified Sharp score and intention-to-treat analysis.3

Enbrel in combination with methotrexate in RA patients

The ADORE trial was a 16 week, randomised, open-label parallel group study in patients with active RA who had an inadequate response to MTX monotherapy despite taking MTX ≥12.5 mg per week for ≥3 months. Patients were randomised to receive either Enbrel 25 mg twice weekly alone (n=160) or in combination with MTX (n=155). The primary endpoint was DAS28 improvement ≥1.2 units. Primary analysis was based on the intent-to-treat population.4

There were no significant differences in ACR 20, 50 and 70 scores at Week 16 between RA patients receiving either Enbrel monotherapy or in combination with MTX.4

Proportion of patients achieving ACR 20, 50 and 70 at Week 16​​​​​​​4

Adapted from Van Riel PL et al 2006.

Summary of the safety profile

The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, bronchitis, bladder infections and skin infections), headache, allergic reactions, development of autoantibodies, itching, and fever.1

Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect the immune system and their use may affect the body's defenses against infection and cancer. Serious infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and life-threatening infections and sepsis. Various malignancies have also been reported with use of Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma).1

Serious haematological, neurological and autoimmune reactions have also been reported. These include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have been rare reports of lupus, lupus-related conditions, and vasculitis.1

Before prescribing Enbrel refer to the full Summary of Product Characteristics which is linked at the bottom of this page.

ACR:American College of Rheumatology; DAS:disease activity score; DMARD:disease modifying anti-rheumatic drug; MTX:Methotrexate; RA:rheumatoid arthritis; TEMPO:Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes.

Please refer to the ENBREL Summary of Product Characteristics for full prescribing information

References:Enbrel Summary of Product CharacteristicsEmery P, et al. Lancet. 2008; 372(9636):375–382.Klareskog L, et al. Lancet. 2004; 363:675–681.Van Riel PL, et al. BMJ. 2006; 65: 1478–1483.

Legal Category: S1A
Further information is available upon request

PP-ENB-IRL-0272 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024